Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update.
Davis
M W
MW
Clinical Development, Amgen Inc, Thousand Oaks, One Amgen Center Drive, Mail Stop 24-1-B, Thousand Oaks, California, 91320-1789, USA. markd@amgen.com
Feige
U
U
Bendele
A M
AM
Martin
S W
SW
Edwards
C K
CK
D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D011092:Polyethylene Glycols / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood / Q000627:therapeutic use*; D047888:Receptors, Tumor Necrosis Factor, Type I; D011994:Recombinant Proteins / Q000097:blood / Q000627:therapeutic use; D053319:Tumor Necrosis Factor Decoy Receptors
D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D011994:Recombinant Proteins; D053319:Tumor Necrosis Factor Decoy Receptors; C069521:recombinant human tumor necrosis factor-binding protein-1; D011092:Polyethylene Glycols